BridgeBio Pharma Quarterly Cash Flow Statement
NASDAQ: BBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BridgeBio Pharma free cash flow
In the quarter ended Jun 30, 2026, BridgeBio Pharma generated -$71.1 million of operating cash flow and spent $443,000 on capital expenditures. That left free cash flow of -$71.5 million, a free-cash-flow margin of -29.4% of revenue. BridgeBio Pharma returned $127.5 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
BridgeBio Pharma cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -155.89M | -166.56M | -194.63M | -184.94M | -183.76M | -169.61M | -267.39M | -164.25M | -75.54M | -36.16M | -170.33M | -179.49M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 1.05M | 1.19M | 1.44M | 1.40M | 1.32M | 1.28M | 1.37M | 1.54M | 1.57M | 1.60M | 1.58M | 1.64M |
| Stock-Based Compensation | 44.07M | 33.24M | 34.64M | 35.26M | 37.24M | 25.88M | 30.13M | 27.16M | 21.45M | 17.06M | 37.02M | 22.60M |
| Change in Working Capital | -27.85M | -79.56M | 16.02M | -29.68M | 41.94M | -94.20M | 6.08M | -6.45M | 248.33M | -215.20M | 2.22M | 825.00K |
| Operating Cash Flow | -71.10M | -197.28M | -56.42M | -109.57M | -80.68M | -199.24M | -195.33M | -180.57M | 74.70M | -219.54M | -124.82M | -145.23M |
| Capital Expenditures | -443.00K | -69.00K | -33.00K | -470.00K | -594.00K | 0 | -47.00K | -137.00K | -54.00K | -695.00K | -435.00K | -431.00K |
| Investing Cash Flow | 17.89M | -42.73M | -14.35M | 4.46M | -13.00M | -1.59M | -3.24M | 38.23M | 3.04M | 22.75M | -66.00K | 37.68M |
| Share Repurchases | -127.50M | -82.50M | 0 | 0 | 0 | -48.28M | 0 | 0 | 0 | 0 | — | — |
| Debt Issued | — | — | — | — | — | — | — | 0 | 0 | 450.00M | — | 0 |
| Debt Repaid | — | — | — | — | 0 | -459.00M | 0 | 0 | 0 | -473.42M | 0 | 0 |
| Financing Cash Flow | -148.77M | 549.89M | -2.18M | -894.00K | 302.04M | 60.33M | 473.93M | 707.00K | -5.73M | 279.55M | -4.52M | 307.04M |
| Net Change in Cash | -201.98M | 309.88M | -72.96M | -106.00M | 208.36M | -140.50M | 275.37M | -141.63M | 72.01M | 82.76M | -129.41M | 199.50M |
| Free Cash Flow | -71.54M | -197.35M | -56.45M | -110.04M | -81.28M | -199.24M | -195.37M | -180.70M | 74.65M | -220.23M | -125.25M | -145.66M |
This table shows 12 quarterly periods of BridgeBio Pharma's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BBIO's reporting calendar. What is a cash flow statement?